GeneDx rallied over 2,500% in 2024 and was the best stock in the market.
What the hell are they doing right?
They've built genome and exome tests and are the first to commercialize it.
It's a total game changer for pediatrics and humanity.
In most cases, children with a rare disease aren't diagnosed until 8 years old.
GeneDx saves lives and money for the American taxpayer by diagnosing life-threatening medical conditions far sooner.
Out of the 3M+ babies born annually, less than 20K were tested. Why so few?
This technology is brand new, and the American Academy of Pediatrics (AAP) has not updated its exome and genome testing guidelines in a decade.
As of today, they tell pediatricians to use these tests as a "last resort."
The good news is AAP is due to revisit its guidelines in 2025, and you can bet your bottom dollar that they'll change the guidelines.
The market is front-running the opportunity, and so are we.
GeneDx $WGS rallied nearly 50% after its last report:
GeneDx is also sporting a beat streak of 4 quarters.
This all started in early 2024 when the company switched from a growth-at-all-costs mindset to one of making money.
It's not just a fundamental story.
The stock chart of $WGS is one of the most actionable in the market.
We often discuss bullish continuation patterns as one of our favorite ways to enter a strong primary uptrend.
That's precisely the situation here. The stock has rallied over 7,000% since its all-time low in late 2023 and has carved out a textbook continuation pattern.
Here's how we're trading GeneDx $WGS:
We're buying $WGS on strength above 84, with a target near 900.
Yes. We think this one is a 10-bagger from current levels.
